Top-Rated StocksTop-RatedNASDAQ:STTK Shattuck Labs (STTK) Stock Price, News & Analysis $6.36 -0.14 (-2.15%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$6.36 +0.00 (+0.08%) As of 09/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Shattuck Labs Stock (NASDAQ:STTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Shattuck Labs alerts:Sign Up Key Stats Today's Range$6.27▼$6.6150-Day Range$5.85▼$8.0652-Week Range$1.70▼$8.33Volume1.39 million shsAverage Volume1.10 million shsMarket Capitalization$638.29 millionP/E RatioN/ADividend YieldN/APrice Target$12.78Consensus RatingBuy Company Overview Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create bifunctional fusion proteins that combine immune-cell activation with the targeted blocking of immune-suppressive pathways. Shattuck’s lead investigational programs are intended to stimulate antitumor immune responses within the tumor microenvironment. Its pipeline has included ARC therapeutics designed to combine CD40 agonism with checkpoint inhibition, including SL-172154, which has been evaluated in clinical studies involving patients with advanced solid tumors. These products remain investigational and have not been approved for commercial use. Founded in 2016 and headquartered in Austin, Texas, Shattuck Labs has advanced its programs through early-stage clinical development and collaborations with research and medical institutions. The company is led by President and Chief Executive Officer Taylor Schreiber, M.D., Ph.D. Shattuck’s shares trade on the Nasdaq under the symbol STTK.AI Generated. May Contain Errors. Read More Shattuck Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSTTK MarketRank™: Shattuck Labs scored higher than 57% of companies evaluated by MarketBeat, and ranked 371st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingShattuck Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialShattuck Labs has a consensus price target of $12.78, representing about 100.9% upside from its current price of $6.36.Amount of Analyst CoverageShattuck Labs has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Shattuck Labs' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Shattuck Labs are expected to decrease in the coming year, from ($0.45) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shattuck Labs is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shattuck Labs is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShattuck Labs has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Shattuck Labs' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.09% of the float of Shattuck Labs has been sold short.Short Interest Ratio / Days to CoverShattuck Labs has a short interest ratio ("days to cover") of 7.59.Change versus previous monthShort interest in Shattuck Labs has recently decreased by 7.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldShattuck Labs does not currently pay a dividend.Dividend GrowthShattuck Labs does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Shattuck Labs this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for STTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Shattuck Labs insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $379,305.00 in company stock.Percentage Held by Insiders8.79% of the stock of Shattuck Labs is held by insiders.Percentage Held by Institutions58.74% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Shattuck Labs' insider trading history. Receive STTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STTK Stock News HeadlinesShattuck Labs, Inc.(NasdaqGS:STTK) added to S&P Biotechnology Select Industry IndexSeptember 21 at 8:51 AM | marketscreener.comMContrasting Shattuck Labs (NASDAQ:STTK) and AnaptysBio (NASDAQ:ANAB)September 20, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Shattuck Labs Announces Participation in Upcoming September Investor ConferencesSeptember 2, 2026 | globenewswire.comShattuck Labs: A Receptor-Side Bet On The TL1A BoomSeptember 1, 2026 | seekingalpha.comShattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value MilestoneAugust 12, 2026 | tipranks.comShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 11, 2026 | markets.businessinsider.comShattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with Phase 2b Crohn’s Study Planned for 2026August 11, 2026 | quiverquant.comQSee More Headlines STTK Stock Analysis - Frequently Asked Questions How have STTK shares performed this year? Shattuck Labs' stock was trading at $3.65 at the beginning of the year. Since then, STTK shares have increased by 74.2% and is now trading at $6.36. How were Shattuck Labs' earnings last quarter? Shattuck Labs, Inc. (NASDAQ:STTK) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.00. When did Shattuck Labs IPO? Shattuck Labs (STTK) raised $178 million in an initial public offering on Friday, October 9th 2020. The company issued 11,882,352 shares at $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI served as the underwriters for the IPO and Needham & Co. was co-manager. Who are Shattuck Labs' major shareholders? Top institutional shareholders of Shattuck Labs include BlackRock Inc. (5.13%), Frazier Life Sciences Management L.P. (3.74%), Wellington Management Group LLP (2.31%) and S&G Foundation (0.57%). Insiders that own company stock include Redmile Group, Llc, Orbimed Advisors Llc, Mona Ashiya, Clay B Siegall, Tyler Brous, Andrew R Neill, Arundathy N Pandite, Abhinav A Shukla, Stephen Stout and Taylor Schreiber. View institutional ownership trends. How do I buy shares of Shattuck Labs? Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Shattuck Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shattuck Labs investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today9/23/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 STTK's financial health is in the Green zone, according to TradeSmith. STTK has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STTK CIK1680367 Webwww.shattucklabs.com Phone512-900-4690FaxN/AEmployees40Year Founded2016Price Target and Rating Average Price Target for Shattuck Labs$12.78 High Price Target$18.00 Low Price Target$7.00 Potential Upside/Downside+100.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.81 million Net MarginsN/A Pretax Margin-5,256.80% Return on Equity-43.57% Return on Assets-40.90% Debt Debt-to-Equity RatioN/A Current Ratio27.59 Quick Ratio27.59 Sales & Book Value Annual Sales$1 million Price / Sales638.29 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book4.89Miscellaneous Outstanding Shares100,360,000Free Float91,541,000Market Cap$638.29 million OptionableOptionable Beta1.09 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:STTK) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
